Home
About
Help
Alert
Account
Login
Advertisement
Advertisement
Back to Search Results
Search
Advanced
Search
Find article
Advanced search
Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX <=2%) hemophilia B patients
Rendo P
;
Barrette-Grischow M-K
;
Smith L
;
Korth-Bradley JM
;
Charnigo R
;
Shafer FE
P. Rendo, Pfizer Inc, Collegeville, PA, United States
Blood. 2012;120((21):): Abstract No. 4628.
Study details
Study Design :
Randomised Controlled Trial